Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells

Arthritis and Rheumatology

Volumn 68, Issue 3, 2016, Pages 627-638

  Patakas, Agapitos ^a   Ji, Rui Ru ^b   Weir, William ^a   Connolly, Sean E ^b   Benson, Robert A ^a   Nadler, Steven G ^b   Brewer, James M ^a   McInnes, Iain B ^a   Garside, Paul ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD71 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HERMES ANTIGEN; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; L SELECTIN; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; ANTIGEN; ANTIRHEUMATIC AGENT; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL CYCLE PROGRESSION; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GENOTYPE; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOREGULATION; MICROARRAY ANALYSIS; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ADOPTIVE TRANSFER; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGY; ISOLATION AND PURIFICATION; T LYMPHOCYTE; TISSUE MICROARRAY; UPREGULATION;

ABATACEPT; ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; ANTIRHEUMATIC AGENTS; CELLS, CULTURED; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MODELS, IMMUNOLOGICAL; RNA; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84963812824     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39470     Document Type: Article

References (60)

1. Goekoop-Ruiterman YP, Huizinga TW., Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol 2010; 6: 68-70.
2. Lenschow DJ, Walunas TL, Bluestone JA., CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
3. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN., Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 2007; 82: 1365-74.
4. Schwartz RH., T cell anergy. Annu Rev Immunol 2003; 21: 305-34.
5. Becker JC, Brabletz T, Kirchner T, Conrad CT, Brocker EB, Reisfeld RA., Negative transcriptional regulation in anergic T cells. Proc Natl Acad Sci 1995; 92: 2375-8.
6. Beverly B, Kang SM, Lenardo MJ, Schwartz RH., Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992; 4: 661-71.
7. Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, Jenkins MK., The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol 1992; 149: 1556-61.
8. Van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ., CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997; 185: 393-404.
9. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-7.
10. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al., Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-8.
11. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al., CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-5.
12. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA., CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-9.
13. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ., Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007; 34: 2204-10.
14. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ., Collagen-induced arthritis in the BB rat: prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995; 96: 987-93.
15. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, et al., Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995; 96: 2195-203.
16. Wells AD, Walsh MC, Bluestone JA, Turka LA., Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001; 108: 895-904.
17. Lakkis FG, Konieczny BT, Saleem S, Baddoura FK, Linsley PS, Alexander DZ, et al., Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158: 2443-8.
18. Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, et al., Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101: 2309-18.
19. Murphy K, Heimberger A, Loh D., Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 1990; 250: 1720-3.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-50.
21. Linsley PS, Nadler SG., The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229: 307-21.
22. Platt AM, Gibson VB, Patakas A, Benson RA, Nadler SG, Brewer JM, et al., Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010; 185: 1558-67.
23. Rush CM, Millington OR, Hutchison S, Bryson K, Brewer JM, Garside P., Characterization of CD4+ T-cell-dendritic cell interactions during secondary antigen exposure in tolerance and priming. Immunology 2009; 128: 463-71.
24. Ko HJ, Cho ML, Lee SY, Oh HJ, Heo YJ, Moon YM, et al., CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population. J Autoimmun 2010; 34: 111-20.
25. Bonelli M, Goschl L, Bluml S, Smolen JS, Scheinecker C., Abatacept (CTLA-4Ig) therapy prevents activation induced cell death (AICD) of regulatory T cells and reduces the susceptibility of T cells to regulatory T cell suppression in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2012; 71 Suppl 1: A10.
26. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L, Juarez-Reyes A, Monsivais-Urenda A, Baranda L, et al., CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31: 588-95.
27. Fu J, Bian M, Jiang Q, Zhang C., Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007; 5: 1-10.
28. Van de Weerdt BC, Medema RH., Polo-like kinases: a team in control of the division. Cell Cycle 2006; 5: 853-64.
29. Safford M, Collins S, Lutz MA, Allen A, Huang CT, Kowalski J, et al., Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 2005; 6: 472-80.
30. Ross EM, Bourges D, Hogan TV, Gleeson PA, van Driel IR., Helios defines T cells being driven to tolerance in the periphery and thymus. Eur J Immunol 2014; 44: 2048-58.
31. Andrew DP, Ruffing N, Kim CH, Miao W, Heath H, Li Y, et al., C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T Cells of both Th1 and Th2 potential. J Immunol 2001; 166: 103-11.
32. Montane J, Bischoff L, Soukhatcheva G, Dai DL, Hardenberg G, Levings MK, et al., Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. J Clin Invest 2011; 121: 3024-8.
33. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al., IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369-77.
34. Van der Voort R, van Lieshout AW, Toonen LW, Sloetjes AW, van den Berg WB, Figdor CG, et al., Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005; 52: 1381-91.
35. Koorella C, Nair JR, Murray ME, Carlson LM, Watkins SK, Lee KP., Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells. J Biol Chem 2014; 289: 7747-62.
36. Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM., Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood 2005; 105: 1574-81.
37. Carman J, Davis P, Yang WP, Zhu J, Chang H, He A, et al., Abatacept does not induce direct gene expression changes in antigen-presenting cells. J Clin Immunol 2009; 29: 479-89.
38. Davis PM, Nadler SG, Stetsko DK, Suchard SJ., Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 2008; 126: 38-47.
39. Shiraishi T, Yasunami Y, Takehara M, Uede T, Kawahara K, Shirakusa T., Prevention of acute lung allograft rejection in rat by CTLA4Ig. Am J Transplant 2002; 2: 223-8.
40. Guillot C, Mathieu P, Coathalem H, Le Mauff B, Castro MG, Tesson L, et al., Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J Immunol 2000; 164: 5258-68.
41. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK., Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411-7.
42. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH., CTLA-4 regulates induction of anergy in vivo. Immunity 2001; 14: 145-55.
43. Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, et al., Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015; 74: 19-26.
44. Boesteanu AC, Katsikis PD., Memory T cells need CD28 costimulation to remember. Semin Immunol 2009; 21: 69-77.
45. Razmara M, Hilliard B, Ziarani AK, Chen YH, Tykocinski ML., CTLA-4×Ig converts CD4+CD25- T cells into CD4+CD25+ regulatory T cells. Int Immunol 2008; 20: 471-83.
46. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA., An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest 2013; 123: 580-93.
47. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ., CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol 2008; 181: 2285-91.
48. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al., CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-101.
49. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, et al., CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004; 200: 1051-62.
50. Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M, et al., IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-γ increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod 2005; 11: 865-70.
51. Bozec A, Zaiss MM, Kagwiria R, Voll R, Rauh M, Chen Z, et al., T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med 2014; 6: 235ra60.
52. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al., Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. Nat Immunol 2004; 5: 1143-8.
53. Shedlock DJ, Shen H., Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300: 337-9.
54. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-3.
55. Johnson-Leger C, Christensen J, Klaus GG., CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells. Int Immunol 1998; 10: 1083-91.
56. Flinsenberg TW, Spel L, Jansen M, Koning D, de Haar C, Plantinga M, et al., Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation. J Virol 2015; 89: 1058-69.
57. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, et al., Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162: 577-84.
58. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, et al., Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 1997; 89: 2635-43.
59. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al., Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012; 7: e35296.
60. Van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, et al., Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010; 69: 1554-61.